In a mouse model of lung cancer, investigators found that IL-2 combined with nanoparticle-mediated MHT treatment increased infiltration of CD4+ and CD8+ T cells, and that tumor growth inhibition was significantly higher with combination treatment (68.1%) compared to IL-2 (14.2%) or MHT alone (45.8%) (156). This evidence concerns the gene IL2 and lung cancer.